Latest News and Press Releases

CRANBURY, N.J., Aug. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that 6 posters highlighting its Fabry program will be included in the 13th International Congress...

First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia Broad Label for Fabry Patients with an Amenable Genetic Mutation CRANBURY, N.J., Aug. 15, 2017 (GLOBE...

            179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 – On Target to Reach 300 Patients by Year-End 2017 Migalastat NDA Submission Targeted for 4Q17 Phase 3 EB...

CRANBURY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on August 7, 2017 at 8:30 a.m. ET to discuss financial...

CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the...

CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the...

CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has...

Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, N.J., July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics...

CRANBURY, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has submitted a Japanese new drug...

CRANBURY, N.J., June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate...